Heat Biologics, Inc. (HTBX) Issues Quarterly Earnings Results
Heat Biologics, Inc. (NASDAQ:HTBX) announced its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.03, Bloomberg Earnings reports. Heat Biologics had a negative return on equity of 148.01% and a negative net margin of 1,479.67%.
Heat Biologics (NASDAQ HTBX) opened at $0.59 on Tuesday. Heat Biologics has a 12-month low of $0.46 and a 12-month high of $3.35.
Separately, Griffin Securities started coverage on Heat Biologics in a report on Tuesday, September 12th. They set a “buy” rating and a $2.25 price target for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $2.13.
A hedge fund recently raised its stake in Heat Biologics stock. Vanguard Group Inc. grew its stake in shares of Heat Biologics, Inc. (NASDAQ:HTBX) by 11.9% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 661,388 shares of the biopharmaceutical company’s stock after buying an additional 70,290 shares during the period. Vanguard Group Inc. owned 1.86% of Heat Biologics worth $403,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 8.64% of the company’s stock.
About Heat Biologics
Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).
Receive News & Ratings for Heat Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.